TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics, a clinical-stage biotech company focused on severe autoimmune diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Marino Garcia will present a corporate overview and meet with investors. The company is also advancing its lead candidate LBL-047 (DNTH212), a bifunctional fusion protein for systemic lupus erythematosus, into Phase 1 trials.

Insights
DNTH   positive

The company is advancing its pipeline with Phase 1 trial initiation for a lead candidate and securing speaking opportunities at a major industry conference, demonstrating progress and investor engagement in the competitive biotech space.